Safety of Amiodarone and Ranolazine Together in Patients With Angina
Unknown statusPhase 4NCT01558830
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Ranolazine is an effective and remarkably safe agent for the treatment of patients with chronic stable angina, but its inhibition of voltage gated potassium channels and electrocardiogram (EKG) corrected QT (QTc) prolongation properties have lead many to question its safety when combined with antiarrhythmic drugs. The investigators have proposed a study to determine the safety of ranolazine in patients with chronic stable angina who also take amiodarone. And are conducting a prospective single-center randomized single-blinded placebo controlled trial to run out of our large cardiology practice setting at Cardiovascular Consultants of Nevada. The hypothesis is that there will be no difference in the ventricular arrhythmia burden. The primary outcome will be the measurement of ventricular arrhythmia episodes on serial holter monitor and other serially acquired recordings (such as electrocardiogram, pacemaker or implantable defibrillator (ICD) data, and stress test data) over a three month trial period.
Study details
- Official title
- Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina
- Conditions
- Chronic Stable Angina
- Coronary Artery Disease
- Atrial Fibrillation
- Ventricular Tachycardia
- Interventions
- Sponsor
- Cardiovascular Consultants of Nevada
- Collaborators
- Gilead Sciences
- Start date
- 2012-01
- Primary completion
- 2013-04
- Sex
- All
- Age range
- from 35 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 3
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * ischemic cardiac disease * chronic anginal symptoms * on amiodarone therapy for other cardiac conditions Exclusion Criteria: * pregnant * non-English speaking * unstable angina * baseline electrocardiogram (EKG) corrected QT (QTc)\>490ms * severe thyroid dysfunction * heart block without a pacer system * liver disease
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01558830